Aquestive Therapeutics Inc [AQST] stock is trading at $6.09, up 16.00%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AQST shares have gain 24.80% over the last week, with a monthly amount glided 127.24%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 14, March 2024, Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting. In a post published today on Yahoo Finance, Anaphylm meets all predefined primary and secondary pharmacokinetic endpoints.
From an analyst’s perspective:
On January 03, 2019, Lake Street initiated with a Buy rating and assigned a price target of $14 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $23 on August 20, 2018. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $29 as its price target on August 20, 2018.
Aquestive Therapeutics Inc [AQST] stock has fluctuated between $0.72 and $5.75 over the past year. Aquestive Therapeutics Inc [NASDAQ: AQST] shares were valued at $6.09 at the most recent close of the market.
Analyzing the AQST fundamentals
Aquestive Therapeutics Inc [NASDAQ:AQST] reported sales of 50.58M for the trailing twelve months, which represents a growth of 23.63%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -0.02%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is 0.07%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is -0.03 and Total Capital is -0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.88.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.57 points at the first support level, and at 5.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.40, and for the 2nd resistance point, it is at 6.70.
Aquestive Therapeutics Inc [AQST] reported earnings per share of -$0.12 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.08/share, meaning a difference of -$0.04 and a surprise factor of -50.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.03 per share as compared to estimates of -$0.11 per share, a difference of $0.08 representing a surprise of 72.70%.
Ratios To Look Out For
For context, Aquestive Therapeutics Inc’s Current Ratio is 2.24. Further, the Quick Ratio stands at 1.87, while the Cash Ratio is 1.3. Considering the valuation of this stock, the price to sales ratio is 8.83.
Transactions by insiders
Recent insider trading involved Schobel Alexander Mark, Chief Innovation/Tech Officer, that happened on Mar 08 ’24 when 25000.0 shares were sold.
